Fludarabine has been associated with an increased risk of opportunistic infections, possibly related to the induction of profound CD4 ϩ lymphopenia. We observed two cases of cytomegalovirus pneumonia (CMV-IP) in a total of nine patients over a 5-year period who had previously received fludarabine and who proceeded to autografting. Both patients also received steroids posttransplant. CMV-IP was observed in one of 104 other autograft recipients over this time who had not received prior fludarabine. This observation suggests that the combination of fludarabine pre-transplant and steroids post-transplant may increase the risk of invasive CMV disease in autograft recipients.
suppressive therapy is a significant risk factor for the development of CMV-IP in this context.
Materials and methods
The case records of the 113 patients were reviewed. The conditioning regimen (TBI-containing or otherwise), CMV serology and prior fludarabine exposure are outlined in Table 1 . Exclusively CMV seronegative or filtered blood products were not used routinely in seronegative patients. Intravenous acyclovir was given in herpes simplex seropositive patients until engraftment; oral aciclovir was not given routinely thereafter.
Case 1
A 42-year-old man underwent an ASCT in July 1995 for progressive low grade non-Hodgkin's lymphoma (NHL). The conditioning regimen consisted of busulphan (16 mg/kg) and melphalan (140 mg/m 2 ). Previous treatment consisted of CVP, CHOP, cyclophosphamide/etoposide and Table 1 Demographics of 111 patients undergoing autografting for lymphoma
Conditioning regimen
Non -TBI  113  TBI  0   CMV serology  Positive  71  Negative  38  Equivocal  1  Not available  3   Prior fludarabine  Yes  9  No  104   Steroids within 3 months post-autograft  Yes  7  Prior to IP  2  Treatment of IP  3  No IP  2  No  106 fludarabine 30 mg/m 2 for 3 days monthly for five courses from July to December 1993. Peripheral blood stem cells were mobilized by cyclophosphamide 2 g/m 2 and G-CSF in August 1994; this was complicated by culture-negative pneumonia. No steroid medication was given in the months prior to transplant. The peripheral blood lymphocyte count was slightly raised on admission (4.2 ϫ 10 9 /l) in the context of extensive marrow involvement. CMV serology was positive and CMV unscreened blood products were transfused as required. Acyclovir was given as herpes simplex virus (HSV) prophylaxis from day 0 until day 44. The initial transplant course was uncomplicated and he was discharged on day 21. On day 27 he was admitted with fever; CXR and bacterial blood cultures were negative. A provisional diagnosis of engraftment syndrome 6 was made and prednisolone 25 mg daily was commenced. On day 41 he developed dyspnea and pulmonary infiltrates. Testing for CMV early antigen in bronchial washings was technically unsatisfactory; CMV cultures were negative. An open lung biopsy on day 44 showed patchy pneumonitis with CMV inclusions. CMV early antigen was negative but cultures were positive. The lymphocyte count over this period was persistently Ͻ0.25 ϫ 10 9 /l. The diagnosis was not made prior to his death on day 55 from respiratory failure. He received treatment during this period with high-dose methylprednisolone; no anti-CMV treatment was given. Post-mortem revealed diffuse alveolar damage with scattered CMV inclusions.
Case 2
A 55-year-old woman underwent an ASCT in January 1995 for diffuse large cell NHL relapsing after CHOP. Two cycles of salvage chemotherapy with fludarabine (30 mg/m 2 ϫ 2), cisplatin (25 mg/m 2 ϫ 4) and cytosine arabinoside (500 mg/m 2 ϫ 2) had been given 3 and 2 months prior to ASCT. Conditioning chemotherapy was busulphan and melphalan. The lymphocyte count pre-admission was 0.02 ϫ 10 9 /l. CMV serology pretransplant was equivocal and blood products were not screened for CMV serology. She was discharged on day 19 and acyclovir was given until day 35. Between day 38 and 50 she developed nausea, peripheral edema, abnormal liver enzyme levels and ascites and was treated with oral dexamethasone 4 mg twice a day at another institution for a presumed diagnosis of progressive lymphoma. Subsequently, she developed progressive lethargy, vomiting and hepatic encephalopathy. CMV early antigen was detected in urine and blood on readmission on day 59. The peripheral blood lymphocyte count was 0.33 ϫ 10 9 /l. A bronchoscopy was performed for deteriorating respiratory function on day 65. CMV early antigen was demonstrated on bronchial washings and culture was positive. Gancyclovir and CMV hyperimmune globulin were administered from day 65 with little benefit and she died on day 73 from respiratory failure. Post-mortem examination revealed hepatic veno-occlusive disease together with CMV inclusions in the lung, liver, stomach, small bowel, colon, bladder and abdominal lymph nodes.
Pneumonitis in the study population
Documented CMV-IP was observed in one of the 104 other ASCT recipients over this time who had not received fludarabine pre-transplant. This patient was refractory to two chemotherapy regimens prior to transplant, and died of multiorgan (including respiratory) failure on day 56; CMV inclusions were seen at bronchoscopy but an open lung biopsy or post-mortem was not performed. This patient did not receive steroids post-transplant.
Four other patients died of non-bacterial or fungal pneumonitis at a median of 56 days (range, 25-180) days posttransplant. Three had pre-or post-mortem histologically documented diffuse alveolar damage and one had end-stage pulmonary fibrosis; none had culture or histological evidence of CMV. Three of these four received steroids for the pneumonitis, but not beforehand.
Two other patients died of infective pneumonia. One developed fatal Legionella pneumonia and died at day 8; the other received fludarabine-based salvage chemotherapy (including prednisolone) for relapse 6 months post-transplant and died of fungal pneumonia in the context of prolonged severe neutropenia.
Prior fludarabine-treated patients
Six of the nine patients were CMV-seropositive. Another (case 2) had equivocal serology and two patients were seronegative. Three patients received steroids post-transplant, including the two who developed CMV-IP. The third received intermittent high-dose dexamethasone for relapsed lymphoma; pulmonary infiltrates developed and Pneumocystis carinii was demonstrated at bronchoscopy despite prophylaxis with nebulised pentamidine.
Steroid therapy post-transplant
A retrospective review of the records revealed that only one other patient (in addition to the three fludarabine-treated patients and the three with non-infective pneumonitis) received prednisolone in the first 3 months post-transplant.
Discussion
This study reviewed the incidence and clinical setting of CMV-IP in 113 consecutive patients undergoing ASCT for lymphoma over a 5-year period. Approximately two-thirds of the patients were CMV-seropositive pretransplant, although the others may have been exposed to the virus, as CMV-seronegative blood products were not used exclusively. CMV-IP occurred in two of seven patients who received steroids post-transplant, three of whom received methylprednisolone after the onset of non-infective pneumonitis; both patients with CMV-IP received steroids posttransplant before the onset of pneumonia. It is possible, therefore, that steroid therapy, by exacerbating the level of immunosuppression which characterizes the early postautograft period 7 was a significant contributor to the development of CMV-IP in the two relevant patients. Consistent with this is the observation that the risk of CMV-IP after allogeneic BMT is much higher in patients with acute GVHD, most of whom receive steroid therapy. 8 Of the three cases of CMV-IP we observed, two occurred in a group of nine patients who had previously received fludarabine, suggesting that prior fludarabine therapy may have contributed to the clinical scenario. There is other evidence to support this hypothesis. Atypical infections have been recognised as a complication of fludarabine-based treatment for low-grade hematological malignancies in the absence of transplantation. 9 It has been postulated that this predisposition may relate to the profound and prolonged lymphopenia, particularly of CD4-positive T lymphocytes, induced by fludarabine; 10 both patients in this report were profoundly lymphopenic post-transplant. The majority of these infections have been Pneumocystis carinii pneumonia (PCP), 11 although CMV disease has been reported in this context. 12, 13 A synergistic effect of steroids and fludarabine in predisposing to opportunistic infections is suggested by the observation of an increased incidence of listeriosis in non-transplant patients receiving both drugs. 14 A significant incidence of herpes zoster and PCP, in the absence of prophylaxis with aciclovir or trimethoprim-sulfamethaxole, has been reported with a fludarabine, mitoxantrone and dexamethasone combination. 15 Of note, the third patient in our study who received fludarabine pretransplant and steroids post-transplant had pneumocystis at bronchoscopy despite pentamidine prophylaxis. The only other published case of a patient treated with fludarabine succumbing to CMV-IP after a subsequent autograft occurred in the context of immune hemolysis early pretransplant which may have been treated with steroids, although this was not specified in the text. 16 TBI has been postulated as a possible risk factor for CMV-IP post-autograft 3 but this was not an issue in our patient population as none received TBI in conditioning. Of note, in one report, none of 110 lymphoma patients autografted after chemotherapy-only conditioning in the prefludarabine era developed CMV-IP or clinically significant CMV infection. 17 While not conclusive, these observations suggest that studies on the quality of immune recovery post-autograft in fludarabine-pretreated patients may be worthwhile. In addition, a high index of suspicion for CMV disease is warranted in patients previously treated with fludarabine who develop unexplained fevers or pulmonary infiltrates postautograft, particularly in the context of concurrent or recent steroid therapy. We now routinely use CMV-seronegative products in fludarabine pretreated CMV-seronegative patients who are being autografted.
